Paris Panayiotopoulos

Paris Panayiotopoulos has more than 20 years of experience in biopharma, where he has primarily focused on growth investments in the biotech space.

Paris came to Blackstone Life Sciences in 2018, as part of the acquisition of Clarus. Before working at Clarus, Paris served as President, CEO, and member of the Board of Directors of ARIAD Pharmaceuticals. He also served as President of North American biopharmaceutical business at Merck KgaA, President of the Serono Research and Development Institute, and President of Merck Serono.

Paris holds a Bachelor of Science from University College London and a Master of Science from Cranfield Business School in the United Kingdom.